Merck KGaA (MRK.F)

Compare

118.40

-3.80

(-3.11%)

At close: April 4 at 6:09:21 PM GMT+2

There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Shareholders appeared unconcerned with Merck KGaA's ( ETR:MRK ) lackluster earnings report last week. We did some...

Simply Wall St. 22 days ago

MKGAF

MKKGY
Merck KGaA (ETR:MRK) Has Announced A Dividend Of €2.20

The board of Merck KGaA ( ETR:MRK ) has announced that it will pay a dividend of €2.20 per share on the 30th of April...

Simply Wall St. 27 days ago

MKGAF

MKKGY
Merck KGaA Full Year 2024 Earnings: EPS Misses Expectations

Merck KGaA ( ETR:MRK ) Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net income...

Simply Wall St. 29 days ago

MKGAF

MKKGY
Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Merck KGaA (MKGAF) reports robust Q4 results with significant growth across sectors, despite challenges in Life Science and Electronics.

GuruFocus.com 29 days ago

MRK.DE
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Pharmaceutical Technology 29 days ago

MRK.DE

GLDAF
Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years

The simplest way to invest in stocks is to buy exchange traded funds. But in our experience, buying the right stocks...

Simply Wall St. 30 days ago

MKGAF

MKKGY
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

The company reported a rise in earnings on temporarily-reduced research and development expenses in its healthcare segment and strict cost discipline.

The Wall Street Journal 30 days ago

MKGAF

MKKGY
Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production. The German group said in a statement that 2025 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would likely reach between 6.1 billion euros ($6.6 billion) and 6.6 billion euros. That would be up from 6.07 billion euros reported for 2024, which was broadly in line with the average analyst estimate.

Reuters 30 days ago

MRK.DE
New CEOs to join Merck KGaA’s executive board

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Pharmaceutical Technology last month

MRK.DE
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market capitalization of $4.02 billion, according to data from Benzinga Pro. Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met. Reuters was the first to report the potent

Benzinga last month

MRK.DE
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

BioPharma Dive last month

THRD

MRK.DE

BBIO
SpringWorks Stock Jumps More Than 30% on News of Possible Deal

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Investopedia last month

MRK.DE
Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires last month

MRK.DE
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. SpringWorks declined to comment.

Reuters last month

MRK.DE
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune last month

PFE

MRK.DE
Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look at where Merck KGaA (OTC:MKGAF) stands against Morgan Stanley’s other European AI stocks. In August last year, investment bank Morgan Stanley released an investor note highlighting that even though the chaos around […]

Insider Monkey 2 months ago

MRK.DE

MS-PQ
Merck and Opentrons to automate assay kits on custom workstation

Customers can order custom workstations and assay kits from Merck later this year.

Medical Device Network 2 months ago

MRK.DE
Merck KGaA's (ETR:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Merck KGaA (ETR:MRK) has had a rough three months with its share price down 14%. But if you pay close attention, you...

Simply Wall St. 3 months ago

MKGAF

MKKGY
Is Merck KGaA (MKKGY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 4 months ago

MRK.DE
Merck KGaA Third Quarter 2024 Earnings: Misses Expectations

Merck KGaA ( ETR:MRK ) Third Quarter 2024 Results Key Financial Results Revenue: €5.27b (up 1.8% from 3Q 2023). Net...

Simply Wall St. 4 months ago

MKGAF

MKKGY

Performance Overview

Return	MRK.F	DAX P (^GDAXI)
YTD	-14.76%	+3.68%
1-Year	-22.54%	+12.16%
3-Year	-34.74%	+42.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MRK.F)

There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Merck KGaA (ETR:MRK) Has Announced A Dividend Of €2.20

Merck KGaA Full Year 2024 Earnings: EPS Misses Expectations

Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

New CEOs to join Merck KGaA’s executive board

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

SpringWorks Stock Jumps More Than 30% on News of Possible Deal

Sector Update: Health Care Stocks Softer Late Afternoon

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

Merck and Opentrons to automate assay kits on custom workstation

Merck KGaA's (ETR:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Is Merck KGaA (MKKGY) Stock Undervalued Right Now?

Merck KGaA Third Quarter 2024 Earnings: Misses Expectations

Performance Overview